MX2024003828A - Métodos de uso de anticuerpos antiesclerostina en el tratamiento de osteogénesis imperfecta. - Google Patents

Métodos de uso de anticuerpos antiesclerostina en el tratamiento de osteogénesis imperfecta.

Info

Publication number
MX2024003828A
MX2024003828A MX2024003828A MX2024003828A MX2024003828A MX 2024003828 A MX2024003828 A MX 2024003828A MX 2024003828 A MX2024003828 A MX 2024003828A MX 2024003828 A MX2024003828 A MX 2024003828A MX 2024003828 A MX2024003828 A MX 2024003828A
Authority
MX
Mexico
Prior art keywords
osteogenesis imperfecta
treatment
methods
sclerostin antibodies
sclerostin antibody
Prior art date
Application number
MX2024003828A
Other languages
English (en)
Spanish (es)
Inventor
Emil Kakkis
Alastair Mackinnon
Arun Mistry
Michael S Ominsky
Original Assignee
Mereo Biopharma 3 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mereo Biopharma 3 Ltd filed Critical Mereo Biopharma 3 Ltd
Publication of MX2024003828A publication Critical patent/MX2024003828A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MX2024003828A 2021-09-30 2022-09-29 Métodos de uso de anticuerpos antiesclerostina en el tratamiento de osteogénesis imperfecta. MX2024003828A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163250918P 2021-09-30 2021-09-30
US202263374982P 2022-09-08 2022-09-08
PCT/US2022/077259 WO2023056355A2 (en) 2021-09-30 2022-09-29 Methods of using anti-sclerostin antibodies in treatment of osteogenesis imperfecta

Publications (1)

Publication Number Publication Date
MX2024003828A true MX2024003828A (es) 2024-05-10

Family

ID=85783647

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024003828A MX2024003828A (es) 2021-09-30 2022-09-29 Métodos de uso de anticuerpos antiesclerostina en el tratamiento de osteogénesis imperfecta.

Country Status (9)

Country Link
US (1) US20250011407A1 (https=)
EP (1) EP4408884A4 (https=)
JP (1) JP2024536106A (https=)
KR (1) KR20240082380A (https=)
AU (1) AU2022357544A1 (https=)
CA (1) CA3233220A1 (https=)
MX (1) MX2024003828A (https=)
TW (1) TW202323278A (https=)
WO (1) WO2023056355A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025212547A1 (en) * 2024-04-05 2025-10-09 Amgen Inc. Methods of treating osteogenesis imperfecta

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011517672A (ja) * 2008-03-24 2011-06-16 アボツト・バイオテクノロジー・リミテツド 骨損失を治療するための方法及び組成物
MA41142A (fr) * 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
KR20190037261A (ko) * 2016-08-08 2019-04-05 암젠 인크 항-스클레로스틴 항체를 사용한 결합 조직 부착 개선 방법
MX2019007161A (es) * 2016-12-21 2020-02-12 Mereo Biopharma 3 Ltd Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
US10961305B2 (en) * 2016-12-21 2021-03-30 Mereo Biopharma 3 Limited Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
GB201810746D0 (en) * 2018-06-29 2018-08-15 Mereo Biopharma 3 Ltd Use of sclerostin antagonist

Also Published As

Publication number Publication date
JP2024536106A (ja) 2024-10-04
EP4408884A2 (en) 2024-08-07
TW202323278A (zh) 2023-06-16
AU2022357544A1 (en) 2024-04-11
CA3233220A1 (en) 2023-04-06
US20250011407A1 (en) 2025-01-09
WO2023056355A2 (en) 2023-04-06
EP4408884A4 (en) 2025-04-23
KR20240082380A (ko) 2024-06-10
WO2023056355A3 (en) 2023-05-19

Similar Documents

Publication Publication Date Title
MX2024013525A (es) Metodos para tratar canceres y potenciar la eficacia de agentes terapeuticos para el redireccionamiento de celulas t
EA201490957A1 (ru) Лечение гематологических злокачественных заболеваний с помощью анти-cxcr4 антитела
MX2024013016A (es) Anticuerpos anti-pd1 para usarse en el tratamiento del cancer
NZ754676A (en) Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
AR082390A1 (es) Terapia de combinacion para tratar el cancer que comprende un inhibidor del igf-1r y un inhibidor de akt
MX2023002554A (es) Anticuerpos anti-il-1r3 humanizados.
PH12022551960A1 (en) Antibodies binding to b7h4
EA202192122A1 (ru) Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения
MX2024001954A (es) Anticuerpos il-13 para el tratamiento de la dermatitis atopica.
MX2020008718A (es) Anticuerpos de union a bcma y usos de los mismos.
ZA201907754B (en) Combination of an erbb-2/erbb-3 bispecific antibody with endocrine therapy for breast cancer
MX2024013613A (es) Anticuerpos il-13 para el tratamiento de la dermatitis atopica
MX2024003828A (es) Métodos de uso de anticuerpos antiesclerostina en el tratamiento de osteogénesis imperfecta.
MX2025001452A (es) Anticuerpos anti-ccr8 y metodos de uso
JOP20230112A1 (ar) أجسام مضادة لـ cd48، متقارنات الجسم المضاد مع العقار، واستخداماتها
MX2023003723A (es) Anticuerpos anti-il-36r para el tratamiento de dolor inflamatorio cronico.
MX2023001111A (es) Metodo para el uso de una molecula pd-1 x ctla-4 biespecifica.
EA202192776A1 (ru) Схемы введения доз и композиции, включающие антитела к rsv
PH12020550066A1 (en) METHOD FOR TREATING TNFa-RELATED DISEASE
EA202192865A1 (ru) Лечение головной боли с использованием антител к cgrp
MY207627A (en) Methods of treating psoriasis
MX2023013165A (es) Molecula de union a antigeno que se une especificamente a rankl y ngf, y su uso medico.
PH12022552038A1 (en) Antigen-binding molecules against alppl2 and/or alpp and uses thereof
MX2024003829A (es) Metodo y sistema para crear una replica de una estructura anatomica.
MX2025003315A (es) Anticuerpos monoclonales anti-ccr8 y su uso terapeutico